PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsVedolizumab
Entyvio(vedolizumab)
Entyvio (vedolizumab) is an antibody pharmaceutical. Vedolizumab was first approved as Entyvio on 2014-05-20. It is used to treat crohn disease, enteritis, and ulcerative colitis in the USA. It has been approved in Europe to treat crohn disease and ulcerative colitis.
Download report
Favorite
Top 200 Pharmaceuticals by Retail Sales
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
digestive system diseasesD004066
Trade Name
FDA
EMA
Entyvio
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Vedolizumab
Tradename
Proper name
Company
Number
Date
Products
EntyviovedolizumabTakedaN-125476 RX2014-05-20
1 products
EntyviovedolizumabTakedaN-761133 RX2023-09-27
1 products
Entyvio PenvedolizumabTakedaN-761133 RX2023-09-27
1 products
Labels
FDA
EMA
Brand Name
Status
Last Update
entyvioBiologic Licensing Application2022-10-24
entyvio entyvio penBiologic Licensing Application2024-06-06
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L04: Immunosuppressants
— L04A: Immunosuppressants
— L04AA: Selective immunosuppressants
— L04AA33: Vedolizumab
HCPCS
Code
Description
J3380
Injection, vedolizumab, 1 mg
Clinical
Clinical Trials
187 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Crohn diseaseD003424EFO_0000384K502413132456
Ulcerative colitisD003093EFO_0000729K511312102349
ColitisD003092EFO_0003872K52.9—312101540
UlcerD014456MPATH_579——312101439
PouchitisD019449EFO_0003921K91.850——11—2
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Inflammatory bowel diseasesD015212EFO_0003767———1—1415
Intestinal diseasesD007410—K63.9——1—45
Sclerosing cholangitisD015209EFO_0004268K83.01——1——1
CholangitisD002761HP_0030151K83.0——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Celiac diseaseD002446EFO_0001060K90.0—1———1
EnteritisD004751—K52.9—1———1
GastritisD005756EFO_0000217K29.7—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———5————5
Hematopoietic stem cell transplantationD018380——1————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
InflammationD007249MP_0001845—————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameVedolizumab
INNvedolizumab
Description
Vedolizumab (humanized mab)
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID—
RxCUI—
ChEMBL IDCHEMBL1743087
ChEBI ID—
PubChem CID—
DrugBankDB09033
UNII ID9RV78Q2002 (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Entyvio – Takeda
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 6,965 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
67,557 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use